Trufanov S V, Subbot A M, Malozhen S A, Salovarova E P, Krakhmaleva D A
Research Institute of Eye Diseases, 11 A, B, Rossolimo St., Moscow, Russian Federation, 119021.
Vestn Oftalmol. 2016;132(6):108-116. doi: 10.17116/oftalma20161326108-116.
Corneal transplantation is the most common and successful type of allotransplantation surgery. Post-transplant immune response in keratoplasty is less pronounced than that in other transplantation procedures, which is accounted for by anatomical features of the cornea and, also, its low antigenic potential and active immunosuppression. However, the immune privilege of the cornea can be violated by neovascularization, inflammation, or trauma. Patients who require keratoplasty to restore their sight and whose immune privilege is disturbed, fall into a high-risk group and are likely to demonstrate tissue incompatibility and non-transparent engraftment. Two approaches exist as to how graft rejection can be prevented. One of them involves induction of donor-specific tolerance, the other - non-specific suppression of the recipient's immune response. To avoid tissue incompatibility, measures can be taken to restore the immune privilege of the cornea as well as to induce antigen-specific tolerance, which is considered a promising, thought yet experimental, area of modern transplantology. In clinical practice, one pays most attention to improvement of non-specific immune suppression methods based on interfering in the metabolism of immunocompetent cells. Thus, timely prescriptions and proper immunosuppressive tactics with account to possible risk factors determine the outcome in high-risk patients undergoing corneal transplantation surgery.
角膜移植是同种异体移植手术中最常见且最成功的类型。角膜移植术后的免疫反应不如其他移植手术明显,这是由角膜的解剖特征以及其低抗原性和主动免疫抑制所导致的。然而,角膜的免疫赦免可能会因新生血管形成、炎症或创伤而受到破坏。需要角膜移植来恢复视力且免疫赦免受到干扰的患者属于高危群体,可能会出现组织不相容和移植片不透明的情况。关于如何预防移植排斥反应存在两种方法。其中一种涉及诱导供体特异性耐受,另一种是对受体免疫反应的非特异性抑制。为避免组织不相容,可以采取措施恢复角膜的免疫赦免以及诱导抗原特异性耐受,这被认为是现代移植学中一个有前景但仍处于实验阶段的领域。在临床实践中,人们最关注基于干扰免疫活性细胞代谢的非特异性免疫抑制方法的改进。因此,及时的处方和适当的免疫抑制策略,并考虑到可能的风险因素,决定了接受角膜移植手术的高危患者的治疗结果。